Bedrocan Cannabis appoints three as independent directors
Bedrocan Cannabis, previously Bedrocan Canada has appointed three independent members to its board of directors, enhancing executive oversight and strengthening the health care experience of the company, a licensed researcher and producer of medicinal cannabis in Canada.
Bedrocan's new independent directors are Barry Fishman, former CEO of Teva Canada; Allan Mandelzys, former CEO and senior executive of publicly-traded biotechnology companies; and Roderick Budd, former life sciences practice leader at Ernst & Young. The new appointees join existing Bedrocan directors Marc Wayne, president and CEO of Bedrocan, and chairman Murray Goldman, the founder and chairman of the Goldman Group.
Fishman has agreed to chair the compensation committee of Bedrocan's board. Previously, as CEO of Taro Canada, a specialty pharmaceutical company, Fishman tripled sales, strengthened talent and improved profitability. Prior to Taro, Fishman spent 17 years with Eli Lilly Canada, where he advanced through several cross-functional leadership roles, including vice president of marketing.
Budd has agreed to chair the audit committee of Bedrocan's board. Budd has over 36 years of experience in public accounting serving emerging and growth companies with a focus on those in the life sciences sector.
Mandelzys is an accomplished biotechnology executive with twenty years of experience, most recently as CEO of a clinical stage, publicly-traded pharmaceutical company. Mandelzys is a business development professional with more than fifteen years of successfully leading negotiations and executing strategic partnerships, which include product in-licensing and out-licensing agreements, merger and acquisition transactions, research alliances and master service agreements.